Inhibitors of the mammalian target of rapamycin (mTOR) are approved for immunosuppression post solid organ transplantation and the treatment of mantle cell lymphoma, breast cancer, neuroendocrine tumors and renal cell cancer. The gene discussed is MTOR; the disease is breast carcinoma.